An interventional study of CMR in Myocardial Infarction With Non-Obstructive Coronary Artery, Myocarditis Acute and Takotsubo Cardiomyopathy, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-21.
Sponsored by University of Zurich · Not applicable, Interventional, and Diagnostic
This clinical study examines patients presenting with acute myocardial infarction and no significant coronary artery disease on coronary angiography (MINOCA) and patients with MINOCA-mimics with advanced CMR.
The present study aims to:
Participants will undergo advanced CMR imaging in the acute setting (within 10 days after event) and post convalescence (after 3 months).
Advanced CMR includes a novel free-breathing motion-informed locally low-rank quantitative 3D myocardial perfusion imaging. Perfusion imaging will be compared with 3D late gadolinium enhancement (LGE) imaging. A cine Dixon sequence is performed for the assessment of epicardial adipose tissue (EAT).
29 studies on the registry are indexed under MINOCA; 18 are open to participants now.
Browse MINOCA studies →University of Zurich is the lead sponsor of 1,049 studies on the registry; 133 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with myocardial infarction with non-obstructive coronary artery disease (MINOCA) prospectively investigated with advanced CMR
Diagnostic Test: CMR
Patients with suspected myocarditis prospectively investigated with advanced CMR
Diagnostic Test: CMR
Patients with suspected Takotsubo cardiomyopathy prospectively investigated with advanced CMR
Diagnostic Test: CMR
Patients with suspected/diagnosed spontaneous coronary artery dissection prospectively investigated with advanced CMR
Diagnostic Test: CMR
Patients with confirmed non-ST elevation myocardial infarction on coronary angiography prospectively investigated with advanced CMR
Diagnostic Test: CMR
Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
Myocardial perfusion reserve index
comparison of microvascular function in the acute phase versus post convalescence
Time frame: within 10 days and after 3 months after index event
epicardial adipose tissue (EAT)
the amount of epicardial adipose tissue
Time frame: 4 months (measured either at first or second CMR)
cardiovascular events
rate of cardiovascular death, myocardial infarction, recurrence of MINOCA, myocarditis, takotsubo cardiomyopathy, SCAD
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Jun 2025, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.